119 related articles for article (PubMed ID: 35227966)
1. Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
Girard N; Galland-Girodet S; Avrillon V; Besse B; Duruisseaux M; Cadranel J; Otto J; Prevost A; Roch B; Bennouna J; Bouledrak K; Coudurier M; Egenod T; Lamy R; Ricordel C; Moro-Sibilot D; Odier L; Tillon-Strozyk J; Zalcman G; Missy P; Westeel V; Baldacci S
ESMO Open; 2022 Apr; 7(2):100418. PubMed ID: 35227966
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer.
Zhao X; Zhang X; Chen H; Bao H; Wu X; Wang H; Bao H; Pang J; Wang S; Wang J
Clin Chem; 2024 Apr; 70(4):629-641. PubMed ID: 38416709
[TBL] [Abstract][Full Text] [Related]
3. In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non-small-cell Lung Cancer.
Schoenmaekers J; Dijkstra J; van der Wekken A; Paats M; Broen M; Brandts L; Dingemans AM; Hendriks L
Clin Lung Cancer; 2024 Mar; 25(2):168-174.e1. PubMed ID: 38151408
[TBL] [Abstract][Full Text] [Related]
4. Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK -rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report.
Jin C; He Z; Guo M; Liu S; Wang Y; Qiu J; Li C; Wu D
Anticancer Drugs; 2022 Aug; 33(7):696-700. PubMed ID: 35324529
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.
Terrones M; Deben C; Rodrigues-Fortes F; Schepers A; de Beeck KO; Van Camp G; Vandeweyer G
J Transl Med; 2024 Mar; 22(1):234. PubMed ID: 38433235
[TBL] [Abstract][Full Text] [Related]
6. Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2.
Liao Y; Remsing Rix LL; Li X; Fang B; Izumi V; Welsh EA; Monastyrskyi A; Haura EB; Koomen JM; Doebele RC; Rix U
Cell Chem Biol; 2024 Feb; 31(2):284-297.e10. PubMed ID: 37848034
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
Liu W; Huo G; Chen P
Front Public Health; 2024; 12():1213318. PubMed ID: 38435286
[TBL] [Abstract][Full Text] [Related]
8. Second-trimester medical abortion after exposure to lorlatinib during early pregnancy, a case report.
Mawet M; Basse C; Barrois M; Gligorov J; Cadranel J; Chabbert-Buffet N; Selleret L
J Gynecol Obstet Hum Reprod; 2023 Dec; 52(10):102673. PubMed ID: 37777070
[TBL] [Abstract][Full Text] [Related]
9. LTK mutations responsible for resistance to lorlatinib in non-small cell lung cancer harboring CLIP1-LTK fusion.
Mori S; Izumi H; Araki M; Liu J; Tanaka Y; Kagawa Y; Sagae Y; Ma B; Isaka Y; Sasakura Y; Kumagai S; Sakae Y; Tanaka K; Shibata Y; Udagawa H; Matsumoto S; Yoh K; Okuno Y; Goto K; Kobayashi SS
Commun Biol; 2024 Apr; 7(1):412. PubMed ID: 38575808
[TBL] [Abstract][Full Text] [Related]
10. Repotrectinib in
Drilon A; Camidge DR; Lin JJ; Kim SW; Solomon BJ; Dziadziuszko R; Besse B; Goto K; de Langen AJ; Wolf J; Lee KH; Popat S; Springfeld C; Nagasaka M; Felip E; Yang N; Velcheti V; Lu S; Kao S; Dooms C; Krebs MG; Yao W; Beg MS; Hu X; Moro-Sibilot D; Cheema P; Stopatschinskaja S; Mehta M; Trone D; Graber A; Sims G; Yuan Y; Cho BC;
N Engl J Med; 2024 Jan; 390(2):118-131. PubMed ID: 38197815
[TBL] [Abstract][Full Text] [Related]
11. Podcast on Lorlatinib as a First-Line Treatment Option for Patients with ALK-Positive Metastatic NSCLC with Brain Metastasis.
Liu G; Lam VK
Adv Ther; 2023 Oct; 40(10):4117-4126. PubMed ID: 37573276
[TBL] [Abstract][Full Text] [Related]
12. A pragmatic guide for management of adverse events associated with lorlatinib.
Liu G; Mazieres J; Stratmann J; Ou SI; Mok T; Grizzard M; Goto Y; Felip E; Solomon BJ; Bauer TM
Lung Cancer; 2024 May; 191():107535. PubMed ID: 38554546
[TBL] [Abstract][Full Text] [Related]
13. Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase (ALK)-positive lung cancer and multiple brain metastases.
Murakami Y; Kawashima Y; Chiba S; Hara S; Yamazaki Y; Doman T; Saito S; Odaka T; Ogasawara T; Shimizu H; Sugisaka J; Aiba T; Toi Y; Yamanda S; Kimura Y; Sugawara S
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1981. PubMed ID: 38212894
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of crizotinib in patients with
Nogami N; Nakamura A; Shiraiwa N; Kikkawa H; Emir B; Wiltshire R; Morise M
Future Oncol; 2023 Dec; 19(37):2453-2463. PubMed ID: 37605861
[TBL] [Abstract][Full Text] [Related]
15. Real-world evidence of lorlatinib therapy in Taiwanese patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer.
Shih JY; Luo YH; Chang GC; Chang JW; Wang CC; Yang TY; Fang WT; Shau WY
J Formos Med Assoc; 2024 Jan; ():. PubMed ID: 38195317
[TBL] [Abstract][Full Text] [Related]
16. Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases.
Metro G; Baglivo S; Metelli N; Bonaiti A; Matocci R; Di Girolamo B; Mandarano M; Colafigli C; Bellezza G; Roila F; Ludovini V
J Chemother; 2023 Oct; 35(6):576-582. PubMed ID: 36537289
[TBL] [Abstract][Full Text] [Related]
17. Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced
Thummalapalli R; Choudhury NJ; Ehrich F; Beardslee T; Brazel D; Zhang SS; Merchant S; Chen MF; Heller G; Ramalingam SS; Ou SI; Mileham KF; Riely GJ
JTO Clin Res Rep; 2023 Aug; 4(8):100546. PubMed ID: 37644967
[TBL] [Abstract][Full Text] [Related]
18. Real world study of safety and efficacy of lorlatinib as second line and beyond in
Biswas B; Ghadyalpatil NS; Patil S; Patel A; Ganguly S; Rathore A; Guleria B; Tarannum CF; Ghosh J; Kondapally MS; Thippeswamy R; Reddy SHP; Roy S
Ecancermedicalscience; 2024; 18():1667. PubMed ID: 38439810
[TBL] [Abstract][Full Text] [Related]
19. Neurocognitive Adverse Events in Patients With ALK or ROS1-Positive, Advanced or Metastatic NSCLC Receiving Lorlatinib.
Zhao B; Wu J; Ma W
J Thorac Oncol; 2023 Mar; 18(3):e26-e27. PubMed ID: 36842815
[No Abstract] [Full Text] [Related]
20. Rapid Response to Lorlatinib in a Patient With TFG-ROS1 Fusion Positive Inflammatory Myofibroblastic Tumor of the Chest Wall Metastatic to the Brain and Refractory to First and Second Generation ROS1 Inhibitors.
Carcamo B; Bista R; Wilson H; Reddy P; Pacheco J
J Pediatr Hematol Oncol; 2021 Jul; 43(5):e718-e722. PubMed ID: 34157012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
